Ovid Therapeutics Inc. (OVID) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-07-08

Ovid Therapeutics Inc. (OVID) has filed 2 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-08. 5 Form 8-K material event filings were reported by OVID in the last 90 days. InsiderAlpha tracks every OVID SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Ovid Therapeutics Inc. (OVID)

SEC CIK	0001636651

90-Day SEC Filing Activity

Form 4 filings (90d)	2
Form 8-K filings (90d)	5
Latest Form 4 filing	2026-07-08

Recent OVID Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-07-06	Carter Charles Ross	Chief Financial Officer	A — Grant or award	50.0K	$0.00	—	SEC
2026-04-07	PAPADOPOULOS STELIOS	Insider	A — Grant or award	17.6K	$2.56	$45K	SEC
2026-04-07	Friedman Bart	Insider	A — Grant or award	8.8K	$2.56	$22K	SEC
2026-04-07	Fitzgerald Kevin Joseph	Insider	A — Grant or award	17.6K	$2.56	$45K	SEC
2026-03-23	LEVIN JEREMY M	Executive Chairman	M — Option exercise	47.3K	$1.40	$66K	SEC
2026-02-26	Rona Jeffrey A	CBFO	A — Grant or award	68.1K	$0.00	—	SEC
2026-02-23	ALEXANDER MARGARET A.	President and CEO	S — Open-market sale	11.7K	$1.45	$17K	SEC
2026-02-23	Rona Jeffrey A	CBFO	S — Open-market sale	8.5K	$1.45	$12K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Ovid Therapeutics Inc. (OVID). Updated in real time as new filings are submitted to the SEC.

Most-Active OVID Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Greka Anna	1	—
Carter Charles Ross	1	—

Recent OVID Form 8-K Material Events

2026-07-08 — Item 5.02 [SEC]
2026-06-11 — Item 5.07 [SEC]
2026-06-03 — Item 5.02 [SEC]
2026-05-12 — Item 9.01 [SEC]
2026-04-20 — Item 8.01 · Financing · positive [SEC]
Ovid Therapeutics' Series A Warrants from its October 2025 private placement expired on April 17, 2026, with investors exercising warrants into 33.6 million shares of common stock and 4.9 million pre-funded warrants, generating approximately $53.9 million in gross proceeds for th

Recent Insider Filings

2026-07-08 — Carter Charles Ross (Chief Financial Officer)
2026-06-17 — Greka Anna (Insider)
2026-04-09 — PAPADOPOULOS STELIOS (Insider)
2026-04-09 — Friedman Bart (Insider)
2026-04-09 — Fitzgerald Kevin Joseph (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in OVID insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

OVID Insider Trading — FAQ

What is the latest insider trade for OVID?: Ovid Therapeutics Inc. (OVID) had 2 insider filings in the last 90 days, with the most recent on 2026-07-08. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying OVID stock?: 0 insider purchases of OVID were filed in the last 90 days.
How many insiders are selling OVID stock?: 0 insider sales of OVID were filed in the last 90 days.
Where can I see OVID SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every OVID SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live OVID dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.